Reimagining Antibody-Based Radiopharmaceuticals: Using Click-to-Release Technology to Expand the Therapeutic Window Across Multiple Targets
11:30 am - Thursday 3rd December 2026
- Leveraging preclinical imaging, dosimetry and translational data to demonstrate how click-to-release technology can selectively remove circulating radioactivity whilst preserving tumour-bound activity
- Exploring how established ADC targets and internalisation pathways can be leveraged to accelerate the development of next-generation radiopharmaceutical programmes
- Examining the potential to overcome historical blood and kidney dose limitations associated with antibody-based radiopharmaceuticals and unlock a broader range of therapeutic targets